Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare Diseases

News   Mar 16, 2018 | Original story from Louisiana State University

 
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare Diseases

Chemotherapeutic vandetanib bound to its main target, Protein Tyrosine Kinase 6, or PTK6, in purple, which is involved in many cancers including gastrointestinal tumors and ovarian cancers. By modeling vandetanib and PTK6 complex, researchers at LSU found the KRAS protein to also contain a similar drug-binding site and therefore to be a good match for the same drug. The computer-generated model of KRAS in gold with vandetanib depicts the predicted interaction. Credit: Misagh Naderi, LSU

 
 
 

RELATED ARTICLES

Protein Target Identified That Could Prevent Strokes

News

Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.

READ MORE

Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug Discovery

News

Scientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.

READ MORE

Crystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity Treatment

News

An international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE